financetom
Business
financetom
/
Business
/
Why JD.Com Stock Is Up 8% Today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why JD.Com Stock Is Up 8% Today
Sep 24, 2024 8:42 AM

JD.Com Inc ( JD ) shares surged 9.06% to $32.46 on Tuesday morning, driven by investor optimism following the announcement of a new stimulus package from China’s Central Bank.

What Investors Need To Know: JD.com’s rise comes in response to the People’s Bank of China’s (PBoC) aggressive monetary easing measures, which are injecting renewed liquidity into China’s financial system and boosting confidence in Chinese equities.

The PBoC’s decision to implement a 50-basis-point cut to the reserve requirement ratio (RRR) for banks, along with a series of rate reductions, has spurred optimism about a recovery in China’s slowing economy. The 50-basis-point RRR cut, which lowers the ratio from 10.0% to 9.5%, is set to release approximately 1 trillion yuan (around $140 billion) into the banking system.

This influx of liquidity gives banks greater capacity to lend, which is expected to stimulate economic activity across multiple sectors, including retail, e-commerce, and logistics—areas where JD.com ( JD ) has a strong presence.

Read Also: Alibaba Partners With Nvidia To Advance AI, Autonomous Driving, Chart Indicates Positive Momentum

What Else: JD.com ( JD ) stands to benefit significantly from the increased consumer spending and economic recovery anticipated from these policies. The liquidity injection is expected to ease credit conditions for both businesses and consumers, potentially increasing consumer purchasing power and leading to higher demand for JD.com’s wide range of products, from electronics and household items to groceries and apparel.

Additionally, the PBoC's move to cut the seven-day repo rate by 20 basis points and the 14-day reverse repo rate by 10 basis points signals further monetary support for businesses.

The combination of lower borrowing costs and enhanced liquidity will likely drive more investment into e-commerce platforms such as JD.com ( JD ), which have been under pressure in the last few quarters due to weakening consumer demand and macroeconomic uncertainties in China.

Read Also: Micron Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

How To Buy JD Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in JD.com’s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, JD has a 52-week high of $35.68 and a 52-week low of $20.82.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Marker Therapeutics Q3 net loss narrows to $2 mln
Marker Therapeutics Q3 net loss narrows to $2 mln
Nov 14, 2025
Overview * Marker Q3 net loss narrows to $2 mln from $2.3 mln yr/yr * MT-601 shows 66% response rate in relapsed NHL patients * Company raises $10 mln through ATM facility, extending cash runway into 2026 Outlook * Marker plans to share additional MT-601 data in the first half of 2026 * Company focuses on enrolling patients in MT-601...
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade
Nov 14, 2025
(Reuters) -Merck ( MRK ) will acquire Cidara Therapeutics ( CDTX ) in a nearly $9.2 billion deal, the companies said, gaining access to an experimental drug for flu prevention. The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare...
Utility Spire's fiscal 2025 adjusted EPS increases
Utility Spire's fiscal 2025 adjusted EPS increases
Nov 14, 2025
Overview * Spire fiscal 2025 adjusted EPS grows 7.5% yr/yr, reflecting operational improvements * Company sets fiscal 2026 and 2027 adjusted EPS guidance * Spire Q4 adjusted EPS misses analyst expectations Outlook * Spire expects fiscal 2026 adjusted EPS of $5.25 to $5.45 * Spire projects fiscal 2027 adjusted EPS of $5.65 to $5.85 * Company reaffirms long-term adjusted EPS...
Neo Performance Materials Q3 revenue beats expectations, raises EBITDA guidance
Neo Performance Materials Q3 revenue beats expectations, raises EBITDA guidance
Nov 14, 2025
Overview * Neo Q3 2025 revenue of $122.2 mln beats analyst expectations * Adjusted EBITDA for Q3 2025 reaches $19.2 mln, slightly down from last year * Company raises full-year 2025 Adjusted EBITDA guidance to $67-71 mln Outlook * Neo raises full-year 2025 Adjusted EBITDA guidance to $67-$71 mln * Neo's new European magnet facility to start production in mid-2026...
Copyright 2023-2026 - www.financetom.com All Rights Reserved